JNJ Stock Overview
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Stjepan Kalinic
Equity Analyst and Writer
Price at publication US$160.48
Updated
Goran Damchevski
Equity Analyst
Price at publication US$160.26
Updated
Johnson & Johnson Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$145.74 |
| 52 Week High | US$175.97 |
| 52 Week Low | US$143.13 |
| Beta | 0.53 |
| 1 Month Change | -6.70% |
| 3 Month Change | -9.86% |
| 1 Year Change | -10.91% |
| 3 Year Change | -11.77% |
| 5 Year Change | 4.36% |
| Change since IPO | 23,218.44% |
Recent News & Updates
Johnson & Johnson: Buy This Bargain Before It's Gone
Apr 18Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds
Apr 11Recent updates
Johnson & Johnson: Buy This Bargain Before It's Gone
Apr 18Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds
Apr 11With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back
Mar 28Johnson & Johnson: A Clean Bill Of Health
Feb 28Is There An Opportunity With Johnson & Johnson's (NYSE:JNJ) 43% Undervaluation?
Feb 12
Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds
Feb 10Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'
Jan 25Shareholder Returns
| JNJ | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.0% | -2.3% | -3.7% |
| 1Y | -10.9% | 11.4% | 20.2% |
Return vs Industry: JNJ underperformed the US Pharmaceuticals industry which returned 11.4% over the past year.
Return vs Market: JNJ underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| JNJ volatility | |
|---|---|
| JNJ Average Weekly Movement | 1.8% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: JNJ has not had significant price volatility in the past 3 months.
Volatility Over Time: JNJ's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 131,900 | Joaquin Duato | www.jnj.com |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.
Johnson & Johnson Fundamentals Summary
| JNJ fundamental statistics | |
|---|---|
| Market cap | US$351.20b |
| Earnings (TTM) | US$19.17b |
| Revenue (TTM) | US$85.65b |
18.3x
P/E Ratio4.1x
P/S RatioIs JNJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNJ income statement (TTM) | |
|---|---|
| Revenue | US$85.65b |
| Cost of Revenue | US$26.27b |
| Gross Profit | US$59.38b |
| Other Expenses | US$40.21b |
| Earnings | US$19.17b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 17, 2024
| Earnings per share (EPS) | 7.96 |
| Gross Margin | 69.33% |
| Net Profit Margin | 22.38% |
| Debt/Equity Ratio | 44.2% |
How did JNJ perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield62%
Payout RatioDoes JNJ pay a reliable dividends?
See JNJ dividend history and benchmarks| Johnson & Johnson dividend dates | |
|---|---|
| Ex Dividend Date | May 20 2024 |
| Dividend Pay Date | Jun 04 2024 |
| Days until Ex dividend | 31 days |
| Days until Dividend pay date | 46 days |
Does JNJ pay a reliable dividends?
See JNJ dividend history and benchmarks